|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...2021222324252627282930...3940» |
- ||| balipodect (TAK-063) / Takeda
Enrollment open: Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants (clinicaltrials.gov) - Dec 19, 2013
P1, N=60, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting
- olanzapine / Generic mfg.
Trial withdrawal: Zyprexa and Task Engagement in Schizophrenia (clinicaltrials.gov) - Dec 18, 2013
P3, N=0, Withdrawn, Sponsor: VA Connecticut Healthcare System
Not yet recruiting --> Recruiting Completed --> Withdrawn
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial initiation date: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Dec 18, 2013
P2, N=37, Recruiting, Sponsor: City of Hope Medical Center
Completed --> Withdrawn Initiation date: Jan 2006 --> Oct 2011
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment change: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Dec 18, 2013
P2, N=37, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Jan 2006 --> Oct 2011 N=11 --> 37
- olanzapine / Generic mfg.
Enrollment change: Zyprexa and Task Engagement in Schizophrenia (clinicaltrials.gov) - Dec 18, 2013
P3, N=0, Withdrawn, Sponsor: VA Connecticut Healthcare System
N=11 --> 37 N=18 --> 0
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Dec 18, 2013
P2, N=37, Recruiting, Sponsor: City of Hope Medical Center
N=18 --> 0 Terminated --> Recruiting
- Enrollment closed: Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders (clinicaltrials.gov) - Dec 18, 2013
P0, N=68, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Terminated --> Recruiting Recruiting --> Active, not recruiting
- Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Grupo Insud, Biocodex, Kuhnil Pharma
Enrollment closed: SMART: Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia (clinicaltrials.gov) - Dec 18, 2013
P4, N=86, Active, not recruiting, Sponsor: Lone Baandrup
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| aripiprazole / Generic mfg.
Enrollment closed: ATTAIN 267: Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. (clinicaltrials.gov) - Dec 18, 2013
P3, N=651, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- ||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (clinicaltrials.gov) - Dec 18, 2013
P3, N=1539, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| aripiprazole / Generic mfg.
Trial completion: ATTAIN 266: Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia (clinicaltrials.gov) - Dec 18, 2013
P3, N=252, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- clonidine / Generic mfg.
Trial completion: Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia? (clinicaltrials.gov) - Dec 18, 2013
P=N/A, N=40, Completed, Sponsor: Birte Glenthoj
Recruiting --> Completed Recruiting --> Completed
- MK-8435 / Merck (MSD)
Enrollment change: GUEST: Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) (clinicaltrials.gov) - Dec 17, 2013
P2, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=200 --> 0
- ||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion: ARRIVE US: Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (clinicaltrials.gov) - Dec 17, 2013
P3, N=504, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=200 --> 0 Active, not recruiting --> Completed
- Enrollment open: GMGWP: Get Moving and Get Well - Pilot Study (clinicaltrials.gov) - Dec 16, 2013
P=N/A, N=30, Recruiting, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- osoresnontrine (BI 409306) / Boehringer Ingelheim
Trial completion: Safety and Tolerability of BI 409306 in Patients With Schizophrenia (clinicaltrials.gov) - Dec 16, 2013
P1, N=40, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial: Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms (clinicaltrials.gov) - Dec 15, 2013
P3, N=50, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- ||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial, Monotherapy: Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia (clinicaltrials.gov) - Dec 15, 2013
P3, N=46, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- ||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial: Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment (clinicaltrials.gov) - Dec 15, 2013
P3, N=50, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Enrollment open: SGE-PsyScan: Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan. (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=648, Recruiting, Sponsor: Maastricht University Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: CM ETG: Contingency Management of Alcohol Abuse in the Severely Mentally ILL (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=120, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment closed: A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics (clinicaltrials.gov) - Dec 13, 2013
P4, N=617, Active, not recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial withdrawal: Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Dec 12, 2013
P2, N=0, Withdrawn, Sponsor: University of Sao Paulo
Recruiting --> Active, not recruiting Suspended --> Withdrawn
- Trial initiation date: Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial (clinicaltrials.gov) - Dec 12, 2013
P=N/A, N=72, Not yet recruiting, Sponsor: King's College London
Suspended --> Withdrawn Initiation date: Sep 2013 --> Jan 2014
- Enrollment change: Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Dec 12, 2013
P2, N=0, Withdrawn, Sponsor: University of Sao Paulo
Initiation date: Sep 2013 --> Jan 2014 N=40 --> 0
- | sodium valproate / Generic mfg.
New P4 trial: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (clinicaltrials.gov) - Dec 11, 2013
P4, N=100, Enrolling by invitation, Sponsor: University of Pittsburgh
- Clinical protocol: Psychosis-Associated Neuroinflammation in Schizophrenia (clinicaltrials.gov) - Dec 10, 2013
P=N/A, N=100, Recruiting, Sponsor: Universiteit Antwerpen
- olanzapine / Generic mfg., clozapine / Generic mfg.
Enrollment open, Adverse events: Alleviating the Metabolic Side Effects of Antipsychotic Medications (clinicaltrials.gov) - Dec 10, 2013
P4, N=90, Recruiting, Sponsor: Baker IDI Heart and Diabetes Institute
N=40 --> 0 Not yet recruiting --> Recruiting
- | aripiprazole / Generic mfg., olanzapine / Generic mfg.
New P4 trial, Adverse events: Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic (clinicaltrials.gov) - Dec 9, 2013
P4, N=340, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- | valacyclovir / Generic mfg.
New P2 trial: A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia (clinicaltrials.gov) - Dec 9, 2013
P2, N=175, Recruiting, Sponsor: Indiana University
- olanzapine / Generic mfg.
Enrollment change, Monotherapy: D-serine Monotherapy for Schizophrenia (clinicaltrials.gov) - Dec 8, 2013
P2, N=18, Completed, Sponsor: Herzog Hospital
Not yet recruiting --> Recruiting N=60 --> 18
- ||| olanzapine / Generic mfg.
Clinical: eVAluatIon of OLanzapine TreatmEnT (clinicaltrials.gov) - Dec 8, 2013
P=N/A, N=500, Not yet recruiting, Sponsor: Elpen Pharmaceutical Co. Inc.
- olanzapine / Generic mfg.
Trial completion, Monotherapy: D-serine Monotherapy for Schizophrenia (clinicaltrials.gov) - Dec 8, 2013
P2, N=18, Completed, Sponsor: Herzog Hospital
N=60 --> 18 Recruiting --> Completed
- Trial completion: L-arginine in Treatment as Usual in Schizophrenia (clinicaltrials.gov) - Dec 8, 2013
P=N/A, N=13, Completed, Sponsor: University of Alberta
Recruiting --> Completed Active, not recruiting --> Completed
- ||| bradanicline (ATA-101) / CODA Biotherap
Enrollment change: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (clinicaltrials.gov) - Dec 5, 2013
P2, N=603, Completed, Sponsor: Targacept Inc.
Active, not recruiting --> Completed N=456 --> 603
- Enrollment change: Predictors of Treatment Outcome for Smokers With and Without Schizophrenia (clinicaltrials.gov) - Dec 5, 2013
P1, N=203, Completed, Sponsor: University of Medicine and Dentistry of New Jersey
N=456 --> 603 N=160 --> 203
- |||| bradanicline (ATA-101) / CODA Biotherap
Trial completion: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (clinicaltrials.gov) - Dec 5, 2013
P2, N=603, Completed, Sponsor: Targacept Inc.
N=160 --> 203 Active, not recruiting --> Completed
- Trial completion: Predictors of Treatment Outcome for Smokers With and Without Schizophrenia (clinicaltrials.gov) - Dec 5, 2013
P1, N=203, Completed, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Completed Active, not recruiting --> Completed
- l-methylfolate / Generic mfg.
Enrollment closed: A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients (clinicaltrials.gov) - Dec 4, 2013
P=N/A, N=50, Active, not recruiting, Sponsor: Pamlab, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| risperidone / Generic mfg., blonanserin / Generic mfg.
Trial completion: Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone (clinicaltrials.gov) - Dec 1, 2013
P3, N=267, Completed, Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial initiation date: Oxytocin as Adjunctive Therapy for Schizophrenia (clinicaltrials.gov) - Nov 25, 2013
P2, N=80, Recruiting, Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli
Recruiting --> Completed Initiation date: Jan 2013 --> Jan 2014
- Enrollment change: A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=71, Completed, Sponsor: Bayside Health
Initiation date: Jan 2013 --> Jan 2014 N=200 --> 71
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment closed, Head-to-Head: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Nov 24, 2013
P3, N=1431, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=200 --> 71 Recruiting --> Active, not recruiting
- |||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion, Adherence: A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate (clinicaltrials.gov) - Nov 24, 2013
P4, N=154, Completed, Sponsor: Janssen Korea, Ltd., Korea
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=71, Completed, Sponsor: Bayside Health
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| aripiprazole / Generic mfg.
Enrollment change: Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials (clinicaltrials.gov) - Nov 21, 2013
P3, N=119, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed N=400 --> 119
- ||| ulotaront (SEP-363856) / Otsuka, PsychoGenics
New P1 trial: Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (clinicaltrials.gov) - Nov 21, 2013
P1, N=60, Recruiting, Sponsor: Sunovion
- ||||||| aripiprazole / Generic mfg.
Trial completion: Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials (clinicaltrials.gov) - Nov 21, 2013
P3, N=119, Completed, Sponsor: Bristol-Myers Squibb
N=400 --> 119 Active, not recruiting --> Completed
- ||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion: Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia (clinicaltrials.gov) - Nov 19, 2013
P3, N=340, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- Trial withdrawal: Once Weekly D-cycloserine for Schizophrenia (clinicaltrials.gov) - Nov 18, 2013
P4, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Completed --> Withdrawn